This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andre, F. Articles by Spielmann, M. Search for Related Content PubMed PubMed Citation Articles by Andre, F. Articles by Spielmann, M. Related Articles Related Correspondence Social Bookmarking                            What's this?

Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period

From the Breast Cancer Unit, Institut Gustave Roussy, Villejuif; Department of Medicine, Centre Leon Berard, Lyon; and Department of Medicine, Centre Antoine Lacassagne, Nice, France

Address reprint requests to Fabrice Andre, MD, Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France; e-mail: fandre{at}igr.fr

PURPOSE: Although new drugs were approved during the 1990s for the treatment of metastatic breast cancer, it is not clear whether their use has changed the outcome of patients in daily practice. This study sought to determine whether survival has improved over time for breast cancer patients who had metastases at diagnosis.

PATIENTS AND METHODS: A total of 724 patients have been treated in three French cancer centers for an initially metastatic breast cancer between 1987 and 2000; 343 were diagnosed between 1987 and 1993, and 381 were diagnosed between 1994 and 2000. Tumor characteristics, treatments, and outcomes of these patients were compared by ² test, log-rank test, and Cox regression analysis.

RESULTS: Characteristics were not different between the patients diagnosed from 1987 to 1993 and those diagnosed from 1994 to 2000. Ten percent of patients treated from 1987 to 1994 and 58% of patients treated from 1994 to 2000 have received either a taxane or a new aromatase inhibitor. The 3-year overall survival rates were 27% for patients treated from 1987 to 1993 and 44% for patients treated from 1994 to 2000 (P < .001). The treatment period (1994 to 2000 v 1987 to 1993) was a prognostic factor in multivariate analysis (relative risk, 0.6; P < .001).

CONCLUSION: The survival of breast cancer patients presenting with metastases at diagnosis has improved over time. This study strongly suggests that this improvement is related to treatment.

Supported by a Young Investigator Award from the American Society of Clinical Oncology (F.A.).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Trends in Survival of Patients With Metastatic Breast Cancer
  Adri C. Voogd, Kitty van Gestel, and Miranda F. Ernst
  JCO 2005 23: 2116 [Full Text]

This article has been cited by other articles:

				L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer Pharmacol. Rev., June 1, 2009; 61(2): 177 - 197. [Abstract] [Full Text] [PDF]

				R. Le Scodan, D. Stevens, E. Brain, J. L. Floiras, C. Cohen-Solal, B. De La Lande, M. Tubiana-Hulin, S. Yacoub, M. Gutierrez, D. Ali, et al. Breast Cancer With Synchronous Metastases: Survival Impact of Exclusive Locoregional Radiotherapy J. Clin. Oncol., March 20, 2009; 27(9): 1375 - 1381. [Abstract] [Full Text] [PDF]

				B. Cady, N. R. Nathan, J. S. Michaelson, M. Golshan, and B. L. Smith Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site Ann. Surg. Oncol., December 1, 2008; 15(12): 3384 - 3395. [Abstract] [Full Text] [PDF]

				R. Largillier, J.-M. Ferrero, J. Doyen, J. Barriere, M. Namer, V. Mari, A. Courdi, J. M. Hannoun-Levi, F. Ettore, I. Birtwisle-Peyrottes, et al. Prognostic factors in 1038 women with metastatic breast cancer Ann. Onc., December 1, 2008; 19(12): 2012 - 2019. [Abstract] [Full Text] [PDF]

				B. Sun, S. Zhang, D. Zhang, Y. Li, X. Zhao, Y. Luo, and Y. Guo Identification of Metastasis-Related Proteins and Their Clinical Relevance to Triple-Negative Human Breast Cancer Clin. Cancer Res., November 1, 2008; 14(21): 7050 - 7059. [Abstract] [Full Text] [PDF]

				S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, A. U. Buzdar, G. N. Hortobagyi, and S. H. Giordano Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer J. Clin. Oncol., October 20, 2008; 26(30): 4891 - 4898. [Abstract] [Full Text] [PDF]

				R. Rao, L. Feng, H. M. Kuerer, S. E. Singletary, I. Bedrosian, K. K. Hunt, M. I. Ross, G. N. Hortobagyi, B. W. Feig, F. C. Ames, et al. Timing of Surgical Intervention for the Intact Primary in Stage IV Breast Cancer Patients Ann. Surg. Oncol., June 1, 2008; 15(6): 1696 - 1702. [Abstract] [Full Text] [PDF]

				J. Fitamant, C. Guenebeaud, M.-M. Coissieux, C. Guix, I. Treilleux, J.-Y. Scoazec, T. Bachelot, A. Bernet, and P. Mehlen Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer PNAS, March 25, 2008; 105(12): 4850 - 4855. [Abstract] [Full Text] [PDF]

				S. A. Khan Primary Tumor Resection in Stage IV Breast Cancer: Consistent Benefit, or Consistent Bias? Ann. Surg. Oncol., December 1, 2007; 14(12): 3285 - 3287. [Full Text] [PDF]

				N. U. Lin and E. P. Winer Brain Metastases: The HER2 Paradigm Clin. Cancer Res., March 15, 2007; 13(6): 1648 - 1655. [Abstract] [Full Text] [PDF]

				A. Gennari, D. Amadori, M. De Lena, O. Nanni, P. Bruzzi, V. Lorusso, L. Manzione, and P. F. Conte Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer J. Clin. Oncol., August 20, 2006; 24(24): 3912 - 3918. [Abstract] [Full Text] [PDF]

				D. G. Kirsch, C. J. Ledezma, C. S. Mathews, A. K. Bhan, M. Ancukiewicz, F. H. Hochberg, and J. S. Loeffler Survival After Brain Metastases From Breast Cancer in the Trastuzumab Era J. Clin. Oncol., March 20, 2005; 23(9): 2114 - 2116. [Full Text] [PDF]

				A. C. Voogd, K. van Gestel, and M. F. Ernst Trends in Survival of Patients With Metastatic Breast Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2116 - 2116. [Full Text] [PDF]

				F. Andre, S. Delaloge, and M. Spielmann In Reply: J. Clin. Oncol., March 20, 2005; 23(9): 2116 - 2117. [Full Text] [PDF]

				M. Fiegl, H. Denz, I. H. Kunkler, C. Tang, A. Y. Lin, A. C. Voogd, K. van Gestel, M. F. Ernst, M. Cristofanilli, L. W.M.M. Terstappen, et al. Circulating Epithelial Cells in Breast Cancer N. Engl. J. Med., December 2, 2004; 351(23): 2452 - 2454. [Full Text] [PDF]